Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan
...currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion. Access has previously announced that it has licensed ProLindac to jiangsu
Aosaikang Pharmaceutical Co., Ltd. ("ASK") for the Greater China Region and to JCOM, Ltd for South Korea. Under these agreements both of these partner...
MIT is pleased to announce that it has signed the Joint Venture agreement with its Chinese partners and has received an initial order of 120 units for Animal vaccination
The name of the joint venture company is "Jiangsu Hualan MIT Medical Technology (MIT China) Ltd" and will be located in Taizhou city in the jiangsu
province. This prime location, supported by the central government, will become the most important medical city in China through the relocation of the...
Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
...n China also finds that increased penetration of current targeted therapies such as AstraZeneca's Iressa (gefitinib), Roche's Tarceva (erlotinib) and jiangsu
Simcere's Endostar (endostatin) and the launch of new targeted therapies -- Roche's Avastin (bevacizumab) and Merck KGaA's Erbitux (cetuximab) -- are ...
Chinese Colorectal Cancer Drug Market Will More Than Double by 2012
...provement in access to medical care and significantly increased prescribing of targeted therapies.
"The increased use of Merck KGaA's Erbitux and jiangsu
Simcere's Endostar and the launch of Roche's Avastin will be the strongest drivers of the Chinese colorectal drug market during the next five years," ...
China-Biotics, Inc. Expands Retail Network to 60 Shining Retail Centers
...roducts are sold over-the-counter
under the "Shining" brand through large distributors to more than 1,000
pharmacies and 100 supermarkets in Shanghai, jiangsu
and Zhejiang. Shining
is one of the most recognized brands in Shanghai. China-Biotics plans to
expand its retail sales to other major cities in China ...
Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
...8 /PRNewswire-FirstCall/ -- Aida
Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that its
recently-acquired research institute in the jiangsu
Province, the Jiangsu
Institute of Microbiology Co., Ltd or "JSIM", is developing a new
wide-spectrum antibiotic, Wetimicin, in the People's Republic ...
Chindex International Announces the Opening of Wuxi United Family Healthcare Center
...nghai. The ceremony was attended by
Ms. Lu Yanguang, Deputy Director of the jiangsu
Entry/Exit Inspection and
Quarantine Bureau, Mr. Gong Peixing, a member of ...ing significant convenience to the expatriate families in
Wuxi and Southern jiangsu
Province, who will gain access to quality medical
care at international sta...
China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
... was also an advanced payment in the amount of RMB13,800,000 (approximately US$1.9 million) made to a organic rice growing project in Donghai, jiangsu
Province, in anticipation of a good harvest year. The advance was not utilized because the actual output of the rice was less than expected. T...
Wyeth to Invest $280 Million to Build State-of-the-Art Nutritional Manufacturing Facility in China
...SE: WYE ) announced today that it is investing $280 million to
build a state-of-the-art nutritional manufacturing facility in Suzhou
Industrial Park, jiangsu
Province, China. The new facility will primarily
produce infant formula milk powder and other nutritional products. When
completed, the site will be o...
Toxic Algae Pose New Health Scare in China
...s Daily newspaper said.
The toxic algae scare in Lake Taihu has already triggered government panic and forced residents of nearby Wuxi city in jiangsu
province to turn off contaminated tapwater supplies. Scientists said that algae was still infecting Lake Taihu and had spread to Chaohu Lake in neighb...
Jiangsu in Medical Technology
Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
...itabine, in multiple solid tumor indications including colorectal and ovarian."
Access has previously announced that it has licensed ProLindac to jiangsu
Aosaikang Pharmaceutical Co., Ltd. ("ASK") for the Greater China Region and to JCOM, Ltd for South Korea. Under these agreements both of these partne...
Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
...c Biopharma Group, Ltd. (PBG), located in San Bruno California and Taizhou, jiangsu
Province, People's Republic of China. The transaction was structured as an ...d China Medical City. It is headquartered in San Bruno, CA and in Taizhou, jiangsu
Province at the China Medical City complex.
NOTE: Other than stateme...
Jiangsu in Medical Dictionary
...m Hydroxide Information, history, uses and where to buy ... Pure potassium hydroxide forms white, deliquescent crystals. ... Jiangsu, China jiangsu
Guangming Chemical Co., Ltd. offers potassium hydroxide . ... We supply high-quality potassium hydroxide , iron content, sulfate content, ... ...
Jiangsu in Biological News
ACS PressPac -- Sept. 17, 2008
DOWNLOAD FULL TEXT ARTICLE
Jiahao Sha, Ph.D.
Nanjing Medical University
Province, People's Republic of China, 210029
ARTICLE #5 EMBARGOED...
Jiangsu in Biological Technology
Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
NANJING, China, May 26 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group
("Simcere" or the "Company") (NYSE: SCR ), a leading manufacturer and supplier
of branded generic and innovative pharmaceuticals in China, today announced an
agreement to acquire a 37.5% stake in Jiangsu
Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
Transaction Value In Excess of $25 Million; Access Gains Second Source Manufacturing And Significant Clinical Trial Support
DALLAS and NANJING, PRC, June 4 /PRNewswire-FirstCall/ -- Access
Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) and Jiangsu
Pharmaceutical Co., LTD....
MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners
...e new order show the beginning of a strong commitment and a step towards a successful long-term relationship between MIT and its Chinese partners.
Hualan MIT Medical Technology (MIT CHINA) Ltd., is actively promoting and selling MIT's unique Agro-Jet(R) needle-free jet injector for animal appli...
Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China
...y produced in China' is the corporate philosophy here which
binds us directly to the ambitious objectives for development of the local
economy and the jiangsu
region," Raster said. At the gala opening he joined
Chao Xingsong, the Managing Director of Gerresheimer Danyang, in welcoming
representatives from th...
China Breaks Ground on Largest Comprehensive Stem Cell Storage and Processing Facility
University, Shanghai Jiao Tong University and jiangsu
Mr. Chen Zhu,...nd abroad.
About China Medical City
Province is considered the number one location for...ated over the past 5 years. The city of Taizhou
is not only the hometown of China's President Hu J...
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
...bination studies later this year."
Access currently has two development and commercialization partners for ProLindac. A licensing agreement with jiangsu
Aosaikang Pharmaceutical Co., Ltd. ("ASK") was signed in 2008 under which ASK will manufacture, develop and commercialize ProLindac for the Greater Ch...
Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
...ifornia, Nanjing Medical
University, the China Medical City, Hua Zhong Technical University, the
University of Texas Health Science Center at Houston, jiangsu
Hospital, the No. 2 Hospital of Nanjing Medical University, and the Wu Hu
City No. 2 People's Hospital in Anhui, China. These mutual cooperat...
Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million
...rtilizers can be manufactured for farming operations. -- In June, Kiwa and jiangsu
Zhongdong Fertilizer Group agreed to develop new compound bio-fertilize...Kiwa Shandong has recently adjusted its product mix in cooperation with jiangsu
Zhongdong Fertilizer Group with a focus on developing new compound bio-...
Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract
...ompany is now applying itself to
adjusting its product mix, developing compound fertilizers and other new
fertilizer products through cooperation with jiangsu
Zhongdong Group. It is
expected that before the end of 2008, part of the Agreements will be
executed with newly developed products."
ABOUT KIWA BIO-...
Global Stem Cell Forum in China Showcases Cutting Edge Research, Focuses on New Findings for iPS Cells
...a's Ministry of Science and Technology
(MOST), the jiangsu
Provincial Department for Science and Technology, ...s attended by MOST officials, the Vice Governor of jiangsu
Zhang Taolin, and Taizhou Mayor Mr. Y...ealthcare."
About the China Medical City (CMC)
Province is considered the number one location for...